New
HealthMore in Health→
New obesity drug data raises questions about Boehringer’s positioning
New data on Boehringer Ingelheim’s obesity drug suggests a mixed profile, with promising liver-fat reductions but less impressive overall weight-loss performance.
Key Takeaways
- The available summary describes a mixed data readout for Boehringer’s obesity drug.
- The strongest positive signal mentioned is reduced liver fat.
DE
DT Editorial Team··via statnews.com